Skip to content
ASH 2013 logo

ASH 2013

2 interviews

American Society of Hematology Annual Meeting

Interviews and expert commentary from ASH 2013 — study authors and key opinion leaders discuss the findings and their clinical implications.

Idelalisib: new targeted therapy improves outlook for patients with chronic lymphocytic leukaemia

Idelalisib: new targeted therapy improves outlook for patients with chronic lymphocytic leukaemia

NEW ORLEANS—A new oral tyrosine kinase inhibitor drug — idelalisib — has proved effective — and to have low toxicity — in patients with chronic lymphocytic leukaemia (CLL). Richard Furman MD from Weil

24 January 2014
First effective treatment for “orphan disease’: Anti I/L 6 antibody brings remissions in Multicentric Castleman’s Disease

First effective treatment for “orphan disease’: Anti I/L 6 antibody brings remissions in Multicentric Castleman’s Disease

The rare, fatal lympho-proliferative condition: Multicentric Castleman’s Disease — MCD — could soon be treatable following findings announced at the American Society of Hematology annual meeting

21 January 2014